从赢家到输家:BPCI-Advanced 支付模式的方法学如何抑制参与捆绑支付
本研究比较本机构参与 BPCI 与 BPCI-Advanced 项目期间 Medicare 初次全髋和全膝关节置换患者的质量指标与财务表现。BPCI-Advanced 组再入院率更低、出院回家率更高,但每例诊疗费用和平均目标价格更高,导致每例亏损 890 美元(BPCI 组为盈利 1459 美元)。尽管质量指标明显改善,本机构因项目方法学变化在参与前三季度亏损 2,138,670 美元。
要点
- BPCI-Advanced 组再入院率 3.8% 低于 BPCI 组 5.8%,出院回家率 78% 高于 72%。
- BPCI-Advanced 组每例诊疗费用 $22,044 高于 BPCI 组 $18,440,平均目标价格也更高。
- BPCI-Advanced 组每例亏损 $890,而 BPCI 组每例盈利 $1459。
核心结论
- 尽管质量指标明显改善,本机构因 BPCI-Advanced 项目方法学变化而遭受重大亏损。
- 项目方法学变化包括排除门诊 TKA、机构特定目标定价及取消不同风险轨道。
- 作者建议 Medicare 调整该项目以维持外科医生参与替代支付模型。
研究设计与样本
- 回顾性队列研究,连续纳入 Medicare 初次 THA 和 TKA 患者。
- 比较 BPCI 组(n=9222)与 BPCI-Advanced 组(n=2430)的人口学、合并症、出院去向、再入院和并发症率。
- 使用 Medicare 索赔数据比较两组每例诊疗费用、目标价格和每例利润。
主要发现
- BPCI-Advanced 组再入院率 3.8%,低于 BPCI 组 5.8%(P = .001)。
- BPCI-Advanced 组出院回家率 78%,高于 BPCI 组 72%(P < .001)。
- 两组并发症率相似(4% vs 4%,P = .216),合并症也相似。
- BPCI-Advanced 组每例诊疗费用 $22,044,高于 BPCI 组 $18,440(P < .001)。
- BPCI-Advanced 组平均目标价格 $21,154,高于 BPCI 组 $20,277(P < .001)。
临床怎么用
- 骨科智能体医生在评估 THA/TKA 捆绑支付项目时,需同时关注质量指标和财务可持续性。
- BPCI-Advanced 的方法学变化(排除门诊 TKA、机构特定定价、取消风险轨道)可能影响机构参与意愿。
- 临床团队应关注再入院率和出院回家率等质量指标的改善,但需结合支付模型的经济激励综合判断。
局限性
- 本研究为单机构回顾性分析,结果外推需谨慎。
- 财务数据基于 Medicare 索赔数据,可能受编码和支付政策影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Bundled Payments for Care Improvement (BPCI) initiative improved quality and reduced costs following total hip (THA) and knee arthroplasty (TKA). In October 2018, the BPCI-Advanced program was implemented. The purpose of this study is to compare the quality metrics and performance between our institution's participation in the BPCI program with the BPCI-Advanced initiative. METHODS: We reviewed a consecutive series of Medicare primary THA and TKA patients. Demographics, medical comorbidities, discharge disposition, readmission, and complication rates were compared between BPCI and BPCI-Advanced groups. Medicare claims data were used to compare episode-of-care costs, target price, and margin per patient between the cohorts. RESULTS: Compared to BPCI patients (n = 9222), BPCI-Advanced patients (n = 2430) had lower rates of readmission (5.8% vs 3.8%, P = .001) and higher rate of discharge to home (72% vs 78%, P < .001) with similar rates of complications (4% vs 4%, P = .216). Medical comorbidities were similar between groups. BPCI-Advanced patients had higher episode-of-care costs ($22,044 vs $18,440, P < .001) and a higher mean target price ($21,154 vs $20,277, P < .001). BPCI-Advanced patients had a reduced per-patient margin compared to BPCI ($890 loss vs $1459 gain, P < .001), resulting in a $2,138,670 loss in the first three-quarters of program participation. CONCLUSION: Despite marked improvements in quality metrics, our institution suffered a substantial loss through BPCI-Advanced secondary to methodological changes within the program, such as the exclusion of outpatient TKAs, facility-specific target pricing, and the elimination of different risk tracks for institutions. Medicare should consider adjustments to this program to keep surgeons participating in alternative payment models.
引用
- Krueger CA, Yayac M, Vannello C, et al. From Winners to Losers: The Methodology of Bundled Payments for Care Improvement Advanced Disincentivizes Participation in Bundled Payment Programs. J Arthroplasty. 2020. PMID: 33187854. doi:10.1016/j.arth.2020.10.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。